Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abbott IndiaBOM:500488 +0.25%87 Days Payable is 108.42 as of Jun. 2026, which is 2% above its 10-year median of 106.79. GuruFocus rates BOM:500488 with a GF Score™ of 87/100 and a GF Value™ of ₹32,428.95 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 925 Drug Manufacturers companies, Abbott India ranks better than 59.89% on this metric.
The historical rank and industry rank for Abbott India's Days Payable or its related term are showing as below:
BOM:500488'
s Days Payable Range Over the Past 10 Years
Min: 74.84 Med: 106.79 Max: 113.05
Current: 105.89
During the past 13 years, Abbott India's highest Days Payable was 113.05. The lowest was 74.84. And the median was 106.79.
BOM:500488's Days Payable is ranked better than 59.89% of 925
companies
in the Drug Manufacturers industry
Industry Median: 88.75
vs BOM:500488: 105.89
Abbott India's Days Payable
increased
from Jun. 2025 (102.46) to Jun. 2026 (108.42).
It may suggest that Abbott Indiadelayed paying its suppliers.
The historical data trend for Abbott India's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Abbott India's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott India Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Abbott India's Days Payable distribution charts can be found below:
* The bar in red indicates where Abbott India's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Abbott India's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott India (BOM:500488) has a Days Payable of 108.42 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Abbott India and its competitors. This is near median its historical median of 106.79. Over the past decade, Abbott India's Days Payable has ranged from 74.84 to 113.05. According to the industry distribution chart, Abbott India ranks #371 out of 925 companies in the Drug Manufacturers industry, placing it in the top 40.1%.
Is Abbott India's Days Payable too high?
Abbott India's current Days Payable of 108.42 is near median its 10-year median of 106.79. Over the past 10 years, this metric has ranged from a low of 74.84 to a high of 113.05. The Drug Manufacturers industry median Days Payable is 88.75. Abbott India's value of 108.42 is 22.2% above this industry median. Based on the distribution chart, Abbott India ranks #371 out of 925 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Abbott India has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbott India's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Abbott India ranks #371 out of 925 companies for Days Payable. This puts Abbott India in the upper half of its industry. The industry median Days Payable is 88.75. Abbott India's value of 108.42 is 22.2% above this benchmark. Historically, Abbott India's own Days Payable has ranged from 74.84 to 113.05 over the past decade. While the company's 10-year median is 106.79 vs. the industry median of 88.75, Abbott India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.75, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott India's current Days Payable of 108.42 is 22.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Abbott India and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott India's current Days Payable is 108.42, which is near median its own 10-year median of 106.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott India stock overvalued right now?
Based on GuruFocus' analysis, Abbott India (BOM:500488) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹32,428.95, compared to a current price of ₹26,501.15 — trading 18.3% below its estimated fair value. The current Days Payable is 108.42, which is near median its 10-year median of 106.79 and 22.2% above the Drug Manufacturers industry median of 88.75. Abbott India's overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Abbott India (BOM:500488), the current Days Payable is 108.42 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott India (BOM:500488) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott India stock appears to be undervalued.
The current stock price of ₹26,501.15 is trading 18.3% below its estimated GF Value™ of ₹32,428.95.
GuruFocus considers Abbott India to be Modestly Undervalued.
Key valuation signals for BOM:500488:
Days Payable: 108.42 (near median its 10-year median of 106.79)
GF Value™: ₹32,428.95 vs. price of ₹26,501.15 (18.3% below fair value)
Industry Position: 22.2% above the Drug Manufacturers median (#371 of 925)
No single metric tells the full story. See the BOM:500488 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott India Ltd is a drug manufacturing company that offers products in diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals. Its patient focus centers overwhelmingly on women's health and gastrointestine, gastroenterology, and hepatic care. Geographically, the majority of the company's revenue is generated in India.
87GF Score
Get the complete analysis for BOM:500488
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500488 has been successfully added to your 
